|
|
|
|
|
|
|
05.06.26 - 18:18
|
AstraZeneca Broadens US Growth Push (Bloomberg)
|
|
|
AstraZeneca CFO Aradhana Sarin discusses how the pharmaceutical company is broadening its US shareholder base and plans to generate $80 Billion in revenue by 2030. She speaks with Bloomberg's Katie Greifeld. (Source: Bloomberg)...
|
|
|
|
|
05.06.26 - 15:06
|
LivaNova Appoints Anne Liddy as Chief Legal Officer (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--$LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company's global legal and compliance function and serve as a member of the Executive Leadership Team.
Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins LivaNova from Hologic, Inc., where she most recently served as General Counsel, leading a global legal organization and advising senior leadership and the Board of Directors on critical business, transactional, and compliance initiatives.
“Anne is a highly accomplished executive with an established record of achievement, guiding organizations through complex regulatory and business environments,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “Her deep healthcare expertise and collaborative,...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.06.26 - 15:18
|
Gesundheit 2030 entscheidet sich heute (News Aktuell)
|
|
|
AstraZeneca GmbH: Hamburg (ots) - Medizinische Innovationen verbessern Versorgung und Forschung rasant, doch regulatorische und geopolitische Entwicklungen setzen den Gesundheitsstandort Deutschland unter Druck. Beim AstraZeneca-Medien-Event "VORschung voraus - ......
|
|
|
|
|
|
|
|
|
04.06.26 - 14:06
|
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 (Business Wire)
|
|
|
- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society's annual meeting, taking place June 13-16, 2026, in Chicago, Illinois.
The late-breaking rapid-fire presentation will include results from Cohort 1 of the placebo-controlled PROGRESS study, which enrolled patients 12 years of age and older and formed the basis of the New Drug Application (NDA) for zilurgisertib to the U.S. Food and Drug Administration (FDA).
In April 2026, Mirum entered into an exclusive license agreement with Incyte for worldwide right...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
